On October 13, 2021 Geneseeq Technology Inc. ("Geneseeq") and Zai Lab, Ltd. ("Zai Lab") (Nasdaq: ZLAB)(HKEX: 9688) reported that new strategic collaboration in Shanghai, China (Press release, Zai Laboratory, OCT 13, 2021, View Source [SID1234591198]). The companies will collaborate to facilitate the R&D and commercialization of Zai Lab’s cancer drugs through business partnerships in clinical trial patient recruitment, central laboratory testing, companion diagnostics development and marketing activities . The announcement was made at the Zai Lab Innovation Summit on October 12th in Shanghai.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Marc Zhao, the co-founder and Chief Operating Officer of Geneseeq delivered a keynote speech on the landscape of gastrointestinal tumor detection and diagnosis during the conference. To conclude, Zhao said that Geneseeq and Zai Lab hope to use this strategic collaboration as the cornerstone to combine resources of both companies to provide high-quality cancer diagnostics and treatment solutions. I look forward to further joint actions between the two parties to improve cancer patient outcomes and generate positive societal impact.
William Liang , Chief Commercial Officer of Zai Lab and President of Greater China said: "In recent years, advances in genetic testing technology have boosted the continuous improvement of precision medicine and treatment programs. Zai Lab has three products listed in China with 10-15 more products expected to be approved. Many of them rely on biomarker testing. We hope to work with genetic testing partners to help patients achieve precise and personalized treatment. At the same time, we also look forward to working with these partners to improve the efficiency of drug research and development, shorten the development cycle, and accelerate product approvals."
The companies look forward to a strong alliance in providing more accurate and efficient treatment plans for patients.